Currently there is no cure for rheumatoid arthritis. Remission of symptoms is more likely when treatment begins early. Nowadays therapies are still allocated on a “trial and error”. Approximately 40% of rheumatoid arthritis patients fail.
A new personalized approach is request
EliChipTM will be connected to the organ-on-chip in order to detect and quantify cytokines, LDH and ROS as inflammation markers.
The same markers are important for many other pathologies!
The ultimate goal of the ITN PREMUROSA project is to train a new generation of scientists with an integrated vision of the whole value chain in musculo-skeletal regeneration technologies and able to boost the necessary innovations to achieve precision principles in developing innovative devices and optimized clinical applications.
Trustech will pool its microfluidic platform and its capability to develop specific surface modifications for other partner’s requests
MARIE SKŁODOWSKA-CURIE ACTIONSResearch Fellowship Programme
Precision medicine for musculoskeletal regeneration, prosthetics, and active ageing